CLAIMS

1. Use of a therapeutically effective amount of niraparib in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of abiraterone acetate, and a therapeutically effective amount of prednisone.

2. Use of a therapeutically effective amount of abiraterone acetate in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of niraparib, and a therapeutically effective amount of prednisone

3. Use of a therapeutically effective amount of prednisone in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of abiraterone acetate, and a therapeutically effective amount of niraparib.

4. Use of a therapeutically effective amount of abiraterone acetate and a therapeutically effective amount of niraparib in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of prednisone.

5. Use of a therapeutically effective amount of abiraterone acetate and a therapeutically effective amount of prednisone in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of niraparib.

6. Use of a therapeutically effective amount of niraparib and a therapeutically effective amount of prednisone in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of abiraterone acetate.

7. Use of a therapeutically effective amount of niraparib in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of abiraterone acetate.

8. Use of a therapeutically effective amount of abiraterone acetate in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of niraparib.

9. Use of a therapeutically effective amount of abiraterone acetate and a therapeutically effective amount of niraparib in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof.

10. Use of a therapeutically effective amount of abiraterone acetate, a therapeutically effective amount of prednisone, and a therapeutically effective amount of niraparib in the manufacture of a medicament for the treatment of a prostate cancer

11. The use according to any one of the preceding claims, wherein the prostate cancer is hormone-sensitive or castration-resistant prostate cancer.

12. The use according to any one of claims 1 to 3 or claims 5 to 8, wherein niraparib and abiraterone acetate, are to be administered to the patient in a single composition.

13. The use according to any one of claims 1 to 3 or claims 5 to 8, wherein niraparib is to be administered in a separate composition from abiraterone acetate.

14. The use according to any one of the preceding claims, wherein niraparib and abiraterone acetate are each to be administered once daily to the patient.

15. The use according to any one of claims 1 to 3 or claims 5 to 8, wherein niraparib is to be administered in a separate composition from the abiraterone acetate and prednisone.

16. The use according to any one of claims 1 to 3, wherein niraparib, abiraterone acetate, and prednisone are each to be administered in separate compositions.

17. The use according to any one of the preceding claims, wherein 500 to 1500 mg/day of the abiraterone acetate is to be administered to the patient.

18. The use according to claim 17 wherein 600 to 1300 mg/day of the abiraterone acetate is to be administered to the patient.

19. The use according to claim 18 wherein 900 to 1100 mg/day of the abiraterone acetate is to be administered to the patient.

20. The use according to claim 19, wherein 1000 mg/day of the abiraterone acetate is to be administered to the patient.

21. The use according to claim 20, wherein 500 mg/day of the abiraterone acetate is to be administered to the patient.

22. The use according to claim 17, wherein 30 to 400 mg/day of the niraparib is to be administered to the patient.

23. The use according to claim 22, wherein 100 to 300 mg/day of the niraparib is to be administered to the patient.

24. The use according claim 23, wherein 175 to 225 mg/day of the niraparib is to be administered to the patient.

25. The use according to claim 20, wherein 200 mg/day of the niraparib is to be administered to the patient.

26. The use according to claim 21, wherein 200 mg/day of the niraparib is to be administered to the patient.

27. The use according to claim 22, wherein 1 to 25 mg/day of the prednisone is to be administered to the patient.

28. The use according to claim 23, wherein 5 to 15 mg/day of the prednisone is to be administered to the patient.

29. The use according to claim 24, wherein 9 to 11 mg/day of the prednisone is to be administered to the patient.

30. The use according to claim 25, wherein 10 mg/day of the prednisone is to be administered to the patient.

31. The use according to claim 26, wherein 10 mg/day of the prednisone is to be administered to the patient.

32. The use according to claim 25, wherein 5 mg/day of the prednisone is to be administered to the patient.

33. The use according to claim 26, wherein 5 mg/day of the prednisone is to be administered to the patient.

34. The use according to any one of the preceding claims, wherein the niraparib, the abiraterone acetate, and the prednisone are to be administered to the patient orally.

35. The use according to any one of the preceding claims, wherein the patient underwent taxane-based chemotherapy prior to the administration of a first dose of the niraparib and the abiraterone acetate.

36. The use according to claim 1, wherein the patient underwent at least one line of androgen receptor-targeted therapy prior to the administration of a first dose of the niraparib and the abiraterone acetate

37. A pharmaceutical composition comprising niraparib and abiraterone acetate in a total amount that is in a single oral dosage form therapeutically effective for the treatment of prostate cancer in a human patient.

38. The composition according to claim 37, wherein said composition is configured for oral administration.

39. The composition according to claim 37 or claim 38 wherein the composition comprises 100 to 350 mg of the niraparib and 100 to 1500 mg of the abiraterone acetate.

40. The composition according to any one of claims 37 to 39, wherein the composition further comprises prednisone or prednisolone.

41. The composition according to claim 40, wherein the composition comprises 2 to 15 mg of prednisone or prednisolone.

42. The composition according to claim 40 or 41, wherein the composition comprises 5 mg of prednisone or prednisolone

43. A pharmaceutical composition comprising niraparib and abiraterone acetate in a total amount that is in multiple oral dosage forms therapeutically effective for the treatment of prostate cancer in a human patient.

44. The composition according to claim 43, wherein said composition is configured for oral administration.

45. The composition according to claim 43 or claim 44, wherein the composition comprises 100 to 350 mg of the niraparib and 100 to 1500 mg of the abiraterone acetate.

46. The composition according to any one of claims 43 to 45, wherein the composition further comprises prednisone or prednisolone.

47. The composition according to claim 46, wherein the composition comprises 2 to 15 mg of prednisone or prednisolone.

48. The composition according to claim 46 or 47, wherein the composition comprises 5 mg of prednisone or prednisolone.